Over the past 12‑18 months the Reagent Grade Lyticase industry trends have accelerated through a series of strategic moves. In March 2024, Thermo Fisher formed a global partnership with biotech start‑up CellNova to co‑develop a high‑purity lyticase formulation tailored for CRISPR‑based yeast editing, expanding distribution across Europe and Asia. July 2024 saw the acquisition of niche supplier MycoPure by Merck KGaA, consolidating market share and integrating MycoPure’s patented enzyme‑stabilization technology into Merck’s product line. In September 2024, Sigma‑Aldrich launched “Lyticase‑Plus”, a lyophilized reagent that promises a 30 % increase in enzymatic activity and a longer shelf‑life, positioning it for the growing demand in high‑throughput screening. Regulatory shifts in the EU’s Biocidal Products Regulation (BPR) now require documented impurity profiles, prompting manufacturers to adopt tighter quality‑control protocols. Meanwhile, venture capital funding of $45 million to biotech incubator BioCatalyst in early 2025 is fueling capacity expansion in North America, addressing the surge in demand from synthetic biology firms. Collectively, these developments signal a maturing market with heightened emphasis on purity, scalability, and compliance.
